Sena et al. showed that growth inhibition of prostate cancer models during BAT requires high AR activity, which is partly driven by the downregulation of MYC, a potent driver of growth and proliferation highly expressed in PCa [93]. This evidence concerns the gene AR and prostate carcinoma.